Healx

Healx is an AI-powered technology company, accelerating the discovery and development of rare disease treatments. Their AI drug discovery platform, Healnet, leverages public and proprietary biomedical data and features a leading knowledge graph for rare diseases, which can help shorten the discovery-to-clinic time to 24 months. Healx’s mission is to advance 100 rare disease treatments towards the clinic by 2025.

The company offers Rareomics, a tool that helps researchers, charities, and individuals keep up with the latest scientific literature on many rare diseases. It also offers Rarepurposing that helps identify existing drug candidates which can help improve the quality of life of patients with rare diseases.

In October 2019 Healx closed a $56m Series B round led by Atomico, with participation from Intel Capital, Global Brain and Btov Partners, amongst others. The financing will be used to develop the company’s therapeutic pipeline and for the launch of its global Rare Treatment Accelerator programme.

Healx Rare Treatment Accelerator, a collaboration programme for select rare disease patient groups and clinicians, launched in 2019. Its aim is to combine knowledge, information and expertise, and to leverage the power of AI so that new treatments can be discovered and progressed towards within 24 months.

In April 2020 Healx revealed it was training its sights on a Covid-19 drug treatment. By analysing possible combination therapies based on existing, approved drugs, it's possible that an effective combination can be found - with none of the clinical trail burden which can delay the introduction of completely new drugs.

Healx was founded in 2014 and is based in Cambridge, United Kingdom.